All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
Rattachement africain : es, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Patients with schizophrenia receiving antipsychotic treatment present lower mortality rates than those who do not. However, the non-adherence rate is high, which can be partially addressed using long-acting injectable (LAI) antipsychotics. The impact of LAI treatments on all-cause mortality compared to oral antipsychotics remains unclear. To fill that gap, a random effects meta-analysis was conducted to analyze the odds ratio (OR) of all-cause, suicidal, and non-suicidal mortality among patients taking LAI antipsychotics compared to oral antipsychotics (PROSPERO:CRD42023391352). Individual and pooled LAI antipsychotics were analyzed against pooled oral antipsychotics. Sensitivity analyses were performed for study design, setting, and industry sponsorship. Meta-regressions were conducted for gender, age, antipsychotic dose, and race. Seventeen articles, total sample 12,042 patients (N = 5795 oral, N = 6247 LAI) were included. Lower risk of all-cause mortality for patients receiving LAI antipsychotics vs receiving oral antipsychotics was found (OR = 0.79; 95%CI = 0.66-0.95). Statistical significance was maintained when only studies comparing the same LAI and oral antipsychotic were included (OR = 0.79; 95%CI = 0.66-0.95; p = <0.01), as well as for non-suicidal mortality (OR = 0.77: 95%CI = 0.63-0.94; p = 0.01), but not for suicidal mortality (OR = 0.86; 95%CI = 0.59-1.26; p = 0.44). Mortality reduction was more pronounced for LAI antipsychotics in first-episode psychosis (FEP) (OR = 0.79; 95%CI = 0.66-0.96) compared to chronic psychosis. No individual LAI reported statistically significant differences against all pooled oral antipsychotics. LAI antipsychotics are associated with a lower risk of all-cause and non-suicidal mortality in individuals with schizophrenia compared to oral antipsychotics. Better adherence to the medication and health services may explain this difference. Whenever possible, the use of LAIs should be considered from the FEP.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
- Date Crossref
- 22/08/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of the Basque Country pays non établi dans la noticeUniversité ou école supérieure
-
BioCruces Health research Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Centro de Investigación Biomédica en Red de Salud Mental pays non établi dans la noticeStructure de recherche
-
Hospital de Basurto pays non établi dans la noticeÉtablissement de santé
-
King's College London Department of Child and Adolescent Psychiatry pays non établi dans la noticeUniversité ou école supérieure
-
South London and Maudsley NHS Foundation Trust Child and Adolescent Mental Health Services pays non établi dans la noticeÉtablissement de santé
-
Hospital General Universitario Gregorio Marañón Department of Child and Adolescent Psychiatry pays non établi dans la noticeÉtablissement de santé
-
Red de Investigación en Actividades Preventivas y Promoción de la Salud pays non établi dans la noticeStructure de recherche
-
Osakidetza pays non établi dans la noticeÉtablissement de santé
-
Osasun Sistemen Ikerketa Institutua pays non établi dans la noticeInstitution
-
National Institute for Health and Care Research pays non établi dans la noticeOrganisme public
-
Hospital Universitario Araba pays non établi dans la noticeÉtablissement de santé
University of the Basque Country, BioCruces Health research Institute et Centro de Investigación Biomédica en Red de Salud Mental, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.